International Ophthalmology

, Volume 33, Issue 5, pp 557–560 | Cite as

Brimonidine–timolol fixed combination induced granulomatous inflammation of the eye

  • María Alejandra Carrasco
  • Bernardo Ariel Schlaen
  • Jorge Oscar Zárate
Case Report


We report on two cases of granulomatous conjunctivitis and uveitis related with the use of a brimonidine–timolol fixed combination. Case report and a review of medical literature. A 64-year-old man was diagnosed with marked granulomatous uveitis and a 57-year-old woman was diagnosed with granulomatous conjunctivitis. Both patients were using a topical fixed combination of brimonidine 0.2 %-timolol 0.5 % for open angle glaucoma. Bilateral granulomatous uveitis and conjunctivitis were diagnosed after 16 months of treatment with a fixed combination of brimonidine–timolol in both cases. Granulomatous inflammation resolved with the cessation of antiglaucomatous drugs and topical corticosteroid treatment. When the inflammation had resolved completely, both patients were rechallenged with topical brimonidine in one eye only to determine causality. Conjunctival hyperemia is a common side effect of glaucoma medications and is sometimes overlooked. Hyperemia may be associated with other signs such as iritis and keratic precipitates or conjunctival inflammation. In such cases, granulomatous inflammation may be considered in the differential diagnosis. The fixed-combination of brimonidine–timolol may cause this clinical picture.


Uveitis Brimonidine Fixed-combination Conjunctivitis Hyperemia Side effects 


Conflict of interest



  1. 1.
    Melamed S, David R (2000) Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther 22:103–111PubMedCrossRefGoogle Scholar
  2. 2.
    Katz LJ (2002) Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 11:119–126PubMedCrossRefGoogle Scholar
  3. 3.
    Sherwood MB, Craven ER, Chou C et al (2006) Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 124:1230–1238PubMedCrossRefGoogle Scholar
  4. 4.
    Motolko MA (2008) Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin 24:2663–2667PubMedCrossRefGoogle Scholar
  5. 5.
    Cano PJ, Diaz-Llopis M (2005) Drug induced uveitis. Arch Soc Esp Oftalmol 80:137–149Google Scholar
  6. 6.
    Becker HI, Walton RC, Diamant JI, Zegans ME (2004) Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 122:1063–1066PubMedCrossRefGoogle Scholar
  7. 7.
    Byles DB, Frith P, Salmon JF (2000) Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 130:287–291PubMedCrossRefGoogle Scholar
  8. 8.
    Alvarado JA (2007) Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol. Arch Ophthalmol 125:717–718PubMedCrossRefGoogle Scholar
  9. 9.
    Acheampong AA, Shackleton M, Tang-Liu DD (1995) Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 23:708–712PubMedGoogle Scholar
  10. 10.
    Nguyen EV, Azar D, Papalkar D, McCluskey P (2008) Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. J Glaucoma 17:40–42PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • María Alejandra Carrasco
    • 1
    • 4
  • Bernardo Ariel Schlaen
    • 2
  • Jorge Oscar Zárate
    • 3
  1. 1.Department of OphthalmologyHospital Universitario de Mendoza, Universidad Nacional de CuyoMendozaArgentina
  2. 2.Department of OphthalmologyHospital de Clínicas “José de San Martín”, Universidad de Buenos AiresCiudad Autónoma de Buenos AiresArgentina
  3. 3.Department of PathologyFacultad de Medicina. Universidad de Buenos AiresCiudad Autónoma de Buenos AiresArgentina
  4. 4.MendozaArgentina

Personalised recommendations